London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market.
Announced today that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at the event and online.
Dr. Gary Jacob, Chief Executive Officer, Dr. Raj Patil, Chief Scientific Officer and the OKYO team, will give a corporate presentation and host 1×1 institutional investor and partnering meetings during the event.
Biotech Showcase:
Presentation Date/Time: Monday January 9, 2023, at 4:30 pm PT
1×1 meetings: January 9-11
Online 1×1 meetings: January 18-19
Location: Hilton San Francisco Union Square in San Francisco, Yosemite-A
To schedule a meeting with management, investors can register on the Biotech Showcase website .
Enquiries:
OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer
+44 (0)20 7495 2379
